Psychopharmacological possibilities in the acute disaster setting.
This article focuses on possible psychopharmacological interventions in the immediate post disaster setting. As there is little evidence for the efficacy or effectiveness of such interventions-given the difficulty in performing randomized, double-blind, placebo controlled studies with these populations-the article will delineate the neurobiological basis for pathological sequelae and theoretical drug interventions targeting putative disease mechanisms.
Simon
Asher
A
Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1230, New York, NY 10029, USA.
Gorman
Jack
J
D000208:Acute Disease; D000679:Amygdala / Q000378:metabolism; D003072:Cognition Disorders / Q000453:epidemiology; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism; D004190:Disasters; D018698:Glutamic Acid / Q000378:metabolism; D006624:Hippocampus / Q000378:metabolism; D006801:Humans; D008569:Memory Disorders / Q000453:epidemiology; D018377:Neurotransmitter Agents / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D017397:Prefrontal Cortex / Q000378:metabolism; D011600:Psychopharmacology / Q000145:classification / Q000379:methods*; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism; D013313:Stress Disorders, Post-Traumatic / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism
D018377:Neurotransmitter Agents; D016194:Receptors, N-Methyl-D-Aspartate; D018698:Glutamic Acid; D003346:Corticotropin-Releasing Hormone; D009638:Norepinephrine